

KNOWLEDGE TRANSFER NETWORK
FOR PREVENTION OF MENTAL DISEASES
AND CANCER IN THE ATLANTIC AREA

You are invited to a conference on “Combining Engineered Antibodies and Marine Products for Biotherapeutics and Diagnostics: Outcomes from the PHARMATLANTIC Consortium”

Tuesday 8th May 2012

National Centre for Sensor Research (Room S206/209), Dublin City University

This conference will highlight the achievements of the PHARMATLANTIC consortium, an EU-funded group, whose aims are focused on the effects of climate change on the production of marine compounds and toxins in the Atlantic area. The partners of this project have already grown, purified and developed models to test the activity of compounds/toxins and are examining their possible applications in a variety of areas including cancer therapy, immunomodulation and neurological diseases.

It is also the first meeting of a proposed annual conference of both industrial and academic groups focusing on antibody production and applications.

This first meeting will focus on key aspects of antibody generation and use with particular emphasis on synergies with marine toxicology and marine products.

Conference Programme

8.30 – 9.00 Registration

9.00 – 9.15 Opening and Welcome – Prof. Brian MacCraith, President DCU

9.15 – 9.30 Introduction – Prof. Richard O’Kennedy

9.30 – 10.10 The Atlantox and Pharmatlantic consortium: objectives and achievements – Prof. Luis M. Botana, Univ Santiago Compostela

10.10 – 10.30 Rapid antibody-based assays for marine toxins -Prof Chris Elliott, Queens University, Belfast

10.30 – 10.50 Development of high sensitivity assays for marine toxins and other molecules using Mass Spectrometry – Dr. Ambrose Furey, Cork Institute of Technology (CIT)

10.50 – 11.15 Tea/Coffee and Poster Session

11.15 – 11.35 High sensitivity assay development using recombinant antibodies – Prof. Richard O’Kennedy, Dublin City University

11.35 – 11.55 Antibody toxin conjugates for oncology applications – Dr. Marc Damelin, Pfizer Oncology Research Unit, Pearl River

11.55 – 12.35 Biotherapeutic antibody engineering at Pfizer – Dr. Jonny Finlay, Pfizer Global

Biotherapeutics, Grangecastle

12.35 – 13.30 Lunch

13.30 – 14.45 Key issues related to industrial production and validation of antibodies- Focus group discussion lead by Mr. Declan Moran, National Centre for Sensor Research



14.45 – 15.05 Emergent toxins and new toxin vectors in the North Atlantic -Prof. Vitor Vasconcelos, Centro Interdisciplinar de Investigação Marinha e Ambiental (CIIMAR)

15.05 – 15.25 Mode of action of cyclic imines on nicotinic acetylcholine receptors and a receptor binding assay for their detection -Dr Jordi Molgó and Dr Rómulo Aráoz, Centre National de la Recherche Scientifique (CNRS)

15.25 – 16.00 Tea/Coffee and Poster Session

16.00 – 16.30 Determination of glycosylation patterns on proteins including antibodies – Dr. Eoin Cosgrove, National Institute for Bioprocess, Research and Training (NIBRT)

16.30 – 17.10 Keynote address: Title TBC Prof. Michael Berndt, Director Biomedical Diagnostics Institute (BDI)